AASLD 2022
Nov 4 - Nov 8, 2022
Abstract title: GB1211, an oral galectin-3 inhibitor, in decompensated cirrhotic patients: initial findings from the Phase 2 randomized, placebo-controlled GULLIVER-2 trial (late-breaking oral presentation)
Poster title: GULLIVER-2 is an innovative, hybrid, hepatic impairment trial of the oral galectin-3 inhibitor GB1211 (poster presentation)
Poster title: The novel galectin-3 inhibitor GB1211 reduces inflammation & fibrosis in a rabbit high fat diet model of NASH & fibrosis (late-breaking poster presentation)